ES2570332T3 - La combinación de anticolinérgicos y antagonistas del receptor de leucotrieno para el tratamiento de enfermedades respiratorias - Google Patents

La combinación de anticolinérgicos y antagonistas del receptor de leucotrieno para el tratamiento de enfermedades respiratorias

Info

Publication number
ES2570332T3
ES2570332T3 ES06723360T ES06723360T ES2570332T3 ES 2570332 T3 ES2570332 T3 ES 2570332T3 ES 06723360 T ES06723360 T ES 06723360T ES 06723360 T ES06723360 T ES 06723360T ES 2570332 T3 ES2570332 T3 ES 2570332T3
Authority
ES
Spain
Prior art keywords
treatment
combination
respiratory diseases
anticholinergics
receptor antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06723360T
Other languages
English (en)
Spanish (es)
Inventor
Joachim Maus
Beatrix Fyrnys
Torsten Hoffmann
Mario Weingart
Istvan Szelenyi
Peter Cnota
Ullrich Munzel
Ursula Petzold
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meda Pharma GmbH and Co KG
Original Assignee
Meda Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meda Pharma GmbH and Co KG filed Critical Meda Pharma GmbH and Co KG
Application granted granted Critical
Publication of ES2570332T3 publication Critical patent/ES2570332T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ES06723360T 2005-03-16 2006-03-10 La combinación de anticolinérgicos y antagonistas del receptor de leucotrieno para el tratamiento de enfermedades respiratorias Active ES2570332T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66191805P 2005-03-16 2005-03-16
PCT/EP2006/002247 WO2006097250A1 (en) 2005-03-16 2006-03-10 The combination of anticholinergics and leukotriene recptor antagonists for the treatment of repiratory diseases

Publications (1)

Publication Number Publication Date
ES2570332T3 true ES2570332T3 (es) 2016-05-17

Family

ID=36570797

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06723360T Active ES2570332T3 (es) 2005-03-16 2006-03-10 La combinación de anticolinérgicos y antagonistas del receptor de leucotrieno para el tratamiento de enfermedades respiratorias

Country Status (18)

Country Link
US (1) US8268864B2 (cg-RX-API-DMAC7.html)
EP (1) EP1863476B1 (cg-RX-API-DMAC7.html)
JP (1) JP4991693B2 (cg-RX-API-DMAC7.html)
CN (1) CN101128196B (cg-RX-API-DMAC7.html)
AU (1) AU2006224842B2 (cg-RX-API-DMAC7.html)
CA (1) CA2595791C (cg-RX-API-DMAC7.html)
CY (1) CY1117571T1 (cg-RX-API-DMAC7.html)
DK (1) DK1863476T3 (cg-RX-API-DMAC7.html)
ES (1) ES2570332T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20160373T1 (cg-RX-API-DMAC7.html)
HU (1) HUE027076T2 (cg-RX-API-DMAC7.html)
MX (1) MX2007011273A (cg-RX-API-DMAC7.html)
NO (1) NO340405B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ560206A (cg-RX-API-DMAC7.html)
PL (1) PL1863476T3 (cg-RX-API-DMAC7.html)
RU (1) RU2420285C2 (cg-RX-API-DMAC7.html)
SI (1) SI1863476T1 (cg-RX-API-DMAC7.html)
WO (1) WO2006097250A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050048614A1 (en) * 2000-06-13 2005-03-03 Children's Medical Center Corporation Biosynthetic oncolytic molecules and uses therefor
KR20060054408A (ko) * 2003-07-28 2006-05-22 얀센 파마슈티카 엔.브이. 벤즈이미다졸, 벤즈티아졸 및 벤즈옥사졸 유도체 및ｌｔａ4 ｈ 조정자로서의 그의 용도
US7737145B2 (en) 2005-12-29 2010-06-15 Estrellita Pharmaceuticals, Llc Diamine derivatives as inhibitors of leukotriene A4 hydrolase
CL2008000468A1 (es) * 2007-02-14 2008-08-22 Janssen Pharmaceutica Nv Uso de compuestos derivados de heterociclos, inhibidores de leucotrina a4 hidrolasa (lta4h), utiles para tratar o prevenir la dermatitis, acne, infarto al miocardio, dolor, picazon, gingivitis, cancer, artritis, entre otras.
ES2969237T3 (es) 2007-10-18 2024-05-17 Rose U Llc Formulaciones tópicas de glicopirrolato y una toallita que contiene las mismas
NZ584876A (en) * 2007-10-25 2012-06-29 Merck Frosst Canada Ltd Inhalation compositions comprising montelukast acid and a pde-4-inhibitor or an inhaled corticosteroid
EP2440196A4 (en) * 2009-06-09 2013-01-02 Elevation Pharmaceuticals Inc TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY ADMINISTRATION OF BETA 2 NEBULIZED AGONIST OR A COMBINATION OF BETA 2 NEBULIZED AGONIST AND ANTICHOLINERGIC
US9378456B2 (en) * 2012-11-19 2016-06-28 Microsoft Technology Licensing, Llc Task completion
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
WO2014134510A1 (en) 2013-02-28 2014-09-04 Dermira, Inc. Glycopyrrolate salts
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
WO2014164658A1 (en) * 2013-03-12 2014-10-09 Celtaxsys, Inc. Methods of inhibiting leukotriene a4 hydrolase
AU2014240042C1 (en) 2013-03-14 2019-09-05 Celltaxis, Llc Inhibitors of leukotriene A4 hydrolase
CA2935986A1 (en) * 2014-01-10 2015-07-16 Mehar Manku Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
WO2019232306A1 (en) 2018-05-31 2019-12-05 Celtaxsys, Inc. Method of reducing pulmonary exacerbations in respiratory disease patients
EP3908284A4 (en) * 2019-01-10 2023-02-08 EnliTISA (Shanghai) Pharmaceutical Co., Ltd. NEW FORMULATIONS WITH LEUKOTRIEN RECEPTOR ANTAGONISTS
EP4099982A1 (en) * 2020-02-03 2022-12-14 Taro Pharmaceutical Industries Ltd. Topical montelukast formulations
CN115792229B (zh) * 2022-01-28 2024-06-18 华中科技大学同济医学院附属同济医院 鼻分泌物中tPA在制备鼻息肉及其预后检测剂中的应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0435038A (ja) * 1990-05-31 1992-02-05 Oki Electric Ind Co Ltd 半導体素子及びその製造方法
EP0706513B1 (de) 1993-07-02 2002-05-15 Byk Gulden Lomberg Chemische Fabrik GmbH Fluoralkoxy substituierte benzamide und ihre verwendung als zyklisch-nukleotid phosphodiesterase-inhibitoren
US6204285B1 (en) 1996-07-01 2001-03-20 Sepracor Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (R,R)-glycopyrrolate
AU745331B2 (en) * 1996-11-11 2002-03-21 Meda Pharma Gmbh & Co. Kg Pure enantiomer basic aryl-cycloalkyl-hydroxycarboxylic acid esters, process for preparing the same and their use in medicaments
CN1253508A (zh) * 1997-04-30 2000-05-17 沃尼尔－朗伯公司 局部鼻用抗炎组合物
US6384038B1 (en) * 1998-04-14 2002-05-07 Sepracor Inc. Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants
WO1999062720A1 (fr) * 1998-05-29 1999-12-09 Citizen Watch Co., Ltd. Procede permettant de soumettre une imprimante a jet d'encre a un traitement de pre-utilisation
AU749697B2 (en) 1998-08-04 2002-07-04 Jagotec Ag Medicinal aerosol formulations
ATE382386T1 (de) * 1998-11-13 2008-01-15 Jagotec Ag Multidosis-trockenpulverinhalator mit pulverreservoir
DE19921693A1 (de) 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
US6086914A (en) * 1999-03-12 2000-07-11 Weinstein; Robert E. Nonsedating formulations for allergic rhinitis which possess antihistaminic and anticholinergic activity
US20040002548A1 (en) 1999-05-12 2004-01-01 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
SE9903995D0 (sv) * 1999-11-03 1999-11-03 Astra Ab New combination
DE19961300A1 (de) 1999-12-18 2001-06-21 Asta Medica Ag Vorratssystem für Arzneimittel in Pulverform und damit ausgestatteter Inhalator
DE10007203A1 (de) * 2000-02-17 2001-08-23 Asta Medica Ag Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
GB0009583D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
DE10110772A1 (de) 2001-03-07 2002-09-12 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren
AU2002221741B2 (en) * 2000-10-31 2007-04-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative solution formulation containing a tiotropium salt
GB0029903D0 (en) 2000-12-07 2001-01-24 Arakis Ltd Use of anti-muscarinic agents
DE50211045D1 (de) 2001-03-30 2007-11-22 Jagotec Ag Medizinische aerosolformulierungen
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
EP1395288A1 (en) 2001-05-25 2004-03-10 Pfizer Inc. A pde 4 inhibitor and an anti-cholinergic agent in combination for treating obstructive airways diseases
DE60216588T2 (de) 2001-05-25 2007-09-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Kombination eines pde4-inhibitors mit tiotropium zur behandlung obstruktiver atemwegserkrankungen
GB0118373D0 (en) 2001-07-27 2001-09-19 Glaxo Group Ltd Novel therapeutic method
MY148466A (en) * 2001-10-26 2013-04-30 Merck Frosst Canada Ltd Granule formulation
US7258118B2 (en) 2002-01-24 2007-08-21 Sofotec Gmbh & Co, Kg Pharmaceutical powder cartridge, and inhaler equipped with same
ES2275778T3 (es) * 2002-06-06 2007-06-16 Chiesi Farmaceutici S.P.A. Solubilizacion de farmacos en propulsores de hfa mediante emulsiones.
US20040038958A1 (en) 2002-07-11 2004-02-26 Chris Rundfeldt Topical treatment of skin diseases
UA82323C2 (uk) 2002-08-09 2008-04-10 Меда Фарма Гмбх & Ко. Кг Нова комбінація глюкокортикоїду та pde-інгібітору для лікування респіраторних захворювань, алергічних захворювань, астми та хронічних обструктивних легеневих захворювань
AU2003272450A1 (en) * 2002-09-13 2004-04-30 C. Steven Smith Novel composition and method for treatment of upper respiratory conditions
EP1569626A1 (en) * 2002-12-13 2005-09-07 Adagit Pharmaceutical porous particles
EP1452179A1 (en) * 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
ES2300755T3 (es) 2003-03-28 2008-06-16 Nycomed Gmbh Combinacion sinergica que comprende roflumilast y un agente anticolinergico seleccionado de sales de tiotropio para el tratamiento de enfermedades respiratorias.
WO2005055999A1 (ja) 2003-12-08 2005-06-23 Nippon Shinyaku Co., Ltd. 抗コリン作用剤
GB0411056D0 (en) * 2004-05-18 2004-06-23 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
HUE027076T2 (en) 2016-08-29
MX2007011273A (es) 2007-11-08
CA2595791C (en) 2013-10-08
JP4991693B2 (ja) 2012-08-01
SI1863476T1 (sl) 2016-05-31
HRP20160373T1 (hr) 2016-05-06
HK1114013A1 (en) 2008-10-24
NO20075287L (no) 2007-12-05
US20060211729A1 (en) 2006-09-21
CA2595791A1 (en) 2006-09-21
US8268864B2 (en) 2012-09-18
CN101128196B (zh) 2013-01-02
CY1117571T1 (el) 2017-04-26
JP2008533072A (ja) 2008-08-21
NZ560206A (en) 2009-09-25
RU2007138270A (ru) 2009-04-27
NO340405B1 (no) 2017-04-18
WO2006097250A1 (en) 2006-09-21
DK1863476T3 (en) 2016-05-17
EP1863476B1 (en) 2016-02-03
AU2006224842A1 (en) 2006-09-21
PL1863476T3 (pl) 2016-07-29
RU2420285C2 (ru) 2011-06-10
CN101128196A (zh) 2008-02-20
AU2006224842B2 (en) 2011-09-29
EP1863476A1 (en) 2007-12-12

Similar Documents

Publication Publication Date Title
ES2570332T3 (es) La combinación de anticolinérgicos y antagonistas del receptor de leucotrieno para el tratamiento de enfermedades respiratorias
CL2011002787A1 (es) Compuestos derivados de 1-cianoetilheterociclilcarboxamida sustituidos, inhibidores de dipeptidilpeptidasa i (dppi) o catepsina c; composicion farmaceutica; combinacion faramceutica; y su uso en el tratamiento del asma, la enfermedad obstructiva cronica o la rinitis alergica.
CL2008003096A1 (es) Compuestos derivados de piperidino-dihidrotienopirimidinas; inhibidores pde4; composicion farmaceutica que los comprende; y uso en el tratamiento de trastornos o enfermedades de las vias respiratorias o gastrointestinales, como tambien enfermedades inflamatorias de las articulaciones u ojos, entre otras.
CL2011000301A1 (es) Compuestos derivados de purina con actividad inmunomoduladora; composición farmacéutica que los comprende; y uso de ellos en el tratamiento de enfermedades alérgicas, rinitis alérgica, asma, enfermedades infecciosas y cáncer.
SV2010003581A (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
CL2008000307A1 (es) Compuestos derivados de cromen-2-ona sustituido; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como ateroesclerosis, asma, rinitis alergica y epoc.
NO20091413L (no) WNT-antagonister og deres anvendelse i diagnostiseringen og behandlingen av WNT-medierte forstyrrelser
ECSP10010548A (es) Composiciones y metodos de preparacion y uso de las mismas
CY1120741T1 (el) Θεραπεια οζωδους σκληρυνσης
CL2008003694A1 (es) Compuestos derivados de heterociclo-2-carboxamida sustituida; composicion farmaceutica; combinacion farmaceutica; y su uso como inhibidores de dipeptidil peptidasa iv (dpp-iv) en el tratamiento del asma, epoc y rinitis alergica.
CR20110100A (es) Nuevos derivados de sulfamida sustituida
CL2011002056A1 (es) Compuestos derivados del acido {7-([1,2,3]triazol-1-il)-6,7,8,9-tetrahidropirido[1,2-a]indol-10-il}-acetico, antagonista del receptor crth2; composicion farmaceutica que lo comprende; utiles ene l tratamiento del asma, alergias, cancer entre otras.
CL2008001593A1 (es) Compuestos derivados de heterociclos, antagonistas para el ccr2; y uso de los compuestos para tratar afecciones o enfermedades del tracto respiratorio, como enfermedad pulmonar obstructiva cronica y asma.
UY28933A1 (es) Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos
CL2008001818A1 (es) Ácido {4,6-bis(dimetilamino)-2-(4-(4-(trifluorometil)benzamido)bencil)pirimidin-5-il}acético amorfo y sus formas cristalinas i y ii; proceso de preparación; composición farmacéutica; y uso en el tratamiento de enfermedades inflamatorias tales como asma, rinitis alérgica, crohn, entre otras.
UY30846A1 (es) Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
CL2008002954A1 (es) Compuestos derivados de 1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-tetradecahidrociclopenta-(5,6)nafto-(1,2-f)indazol heterociclo o carbociclo sustituido; procedimiento de preparacion; composicion farmaceutica; y su uso en el tratamiento de asma, epoc, rinits alergica.
NI201000079A (es) Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrófilos.
CL2008002864A1 (es) Compuestos derivados de 2-amino-quinolina, antagonistas del receptor de serotonina 5-ht 5a; procedimiento de preparacion;composicion farmaceutica; y uso de los compuestos en la prevencion o el tratamiento de depresion,trastornos de ansiedad,esquizofrenia,trastornos de panico,trastornos de memoria,demencia,entre otros.
CL2008003473A1 (es) Compuestos derivados de fenilpiperidina sustituidos por heterociclos; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso en el tratamiento del trastorno cardiovasculares, tromboembolicos y tumorales; usos in vitro.
CL2013001591A1 (es) Compuestos derivados de triazolopiridina; inhibidores de pde10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, entre otras enfermedades.
BR112015025610A2 (pt) corpo de esmerilhamento
BRPI0919231A2 (pt) agonista de receptor de neuropeptídeo-2, composição farmacêutica que o compreende, seu uso e método para o tratamento ou profilaxia de enfermidades
CL2012000457A1 (es) Composicion farmaceutica oral que comprende el compuesto 1-[2-(2,4-dimetil-fenilsulfanil)-fenil]piperazina y sus sales, en donde dicha composicion esta adaptada de manera que dicho compuesto no es liberado en el estomago; y su uso para el tratamiento de trastornos del animo, de ansiedad, de panico, entre otras enfermedades.
CL2008001817A1 (es) Sales piperazina, benzatina y colina en forma cristalina del acido {4,6-bis(dimetilamino-2-)4-(4-(trifluorometil)benzamido)bencil)pirimidin-5-il)acético; proceso de preparación; composición farmacéutica; y uso en el tratamiento de enfermedades inflamatorias tales como asma, rinitis alérgica, crohn, entre otras.